维克萨雷利马布在患有 Prurigo Nodularis 的患者中:一个随机临床试验
Sonja Ständer1, Gil Yosipovitch2, Howard Sofen3
1Section for Pruritus Medicine, Department of Dermatology, Münster University Hospital, Münster, Germany.
JAMA dermatology
|December 17, 2025
概括
维沙雷利马布显著降低了和皮肤病变在患有prurigo nodularis (PN) 的患者. 这一2b期试验显示了剂量依赖的益处和新PN治疗的有利安全概况.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 临床试验 临床试验
背景情况:
- 节炎 (PN) 是一种慢性炎症性皮肤疾病,导致严重的和结节,不需要有效的治疗方法.
- 目前用于PN的治疗方法提供有限的缓解,并不能完全解决疾病进展或患者的生活质量.
研究的目的:
- 评估vixarelimab在中度至重症PN患者中的疗效,安全性,耐受性和药理动力学.
- 在2b期临床试验中评估每月服用vixarelimab的剂量依赖性影响.
主要方法:
- 一项为期16周的双盲,安慰剂控制,随机临床试验,涉及190名患有PN的参与者.
- 参与者每4周一次接受vixarelimab (120毫克,360毫克或540毫克) 或安慰剂的皮下注射.
- 主要结局包括"最坏的 numeric评分尺度 (WI-NRS) "和PN调查员全球评估得分的变化.
主要成果:
- 与安慰剂相比,vixarelimab在所有测试剂量中显著降低了WI-NRS得分.
- 接受vixarelimab治疗的患者比例较高,实现了临床上有意义的减少 (≥4点WI-NRS降低),并改善了PN调查员全球评估得分.
- 没有报告致命或严重的与药物相关的不良事件,这表明了有利的安全性.
结论:
- 维沙雷利马布在结节炎患者中表现出快速,持续和剂量依赖的临床益处.
- 这项研究支持vixarelimab作为一种潜在的新疗法选择,用于管理PN症状并改善患者的治疗结果.
- 需要在更大的试验中进行进一步的研究,以证实这些发现并确定最佳的剂量策略.
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:16Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
01:14Changes in Skin Color: Clinical Perspectives
The first thing a clinician sees is the skin, so the examination of the skin should be part of any thorough physical examination. Most skin disorders are relatively benign, but a few, including melanomas, can be fatal if untreated. A couple of the more noticeable disorders, albinism and vitiligo, affect the appearance of the skin and its accessory organs.
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
Albinism
Albinism is a genetic disorder that affects (completely or partially) the coloring of skin, hair, and eyes. The defect is primarily...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates these...